Application of NLRC5 in preparation of sepsis diagnostic kit

By using NLRC5 as a biomarker in the sepsis diagnosis kit, the level of NLRC5 in plasma is detected by using enzyme-linked immunosorbent assay technology, the problems of complexity and inaccuracy of sepsis diagnosis in the prior art are solved, and the problem of High specificity and sensitivity diagnostic results, and have the advantages of simple operation and low cost.

CN119064599AInactive Publication Date: 2024-12-03南昌大学第一附属医院

Patent Information

Application Number
CN202411349295.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The lack of effective biomarkers in the diagnosis of sepsis results in complex and inaccurate diagnosis.

Method used

NLR family CARD domain protein 5 (NLRC5) was used as a biological marker of IgA, and NLRC5 levels in plasma were detected in the sepsis diagnostic kit by enzyme-linked immunosorbent assay technology (such as the ELISA assay kit).

Benefits of technology

It achieves high specificity, good sensitivity in the diagnosis of sepsis, simple operation, no intervention, low cost, and no radiation hazard, providing high-accurate diagnostic results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064599A_ABST
    Figure CN119064599A_ABST
Patent Text Reader

Abstract

The invention discloses an application of NLRC5 in preparation of a sepsis diagnostic kit.The sepsis diagnostic kit adopts the NLRC5 as a biological marker of IgA, is an ELISA detection kit and comprises a microporous ELISA plate and a standard substance corresponding to the NLRC5, the kit comprises a substrate, a sample diluent, a horse radish peroxidase labeled detection antibody, a washing buffer, a substrate, a stop buffer and a plate sealing membrane. The NLRC5 in the plasma is used as an auxiliary diagnosis index of sepsis, and the sepsis diagnosis kit is high in diagnosis specificity and good in sensitivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to the application of NLRC5 in preparing a sepsis diagnosis kit. Background Art

[0002] Sepsis is a syndrome caused by infection and characterized by systemic multi-organ dysfunction. Currently, patients with suspected sepsis are diagnosed according to the Sepsis-3 sepsis diagnostic criteria. The treatment principles for patients with sepsis include anti-infection, fluid resuscitation, and multi-organ function support therapy. With the development of the national economy and the improvement of medical standards, attention to the diagnosis and treatment of sepsis continues to increase, but the cause and pathogenesis of sepsis in the intensive care unit are not yet fully understood. At present, sepsis is considered to be a complex disease based on infection, mediated by innate and adaptive immune system disorders, and involving multiple factors such as coagulation disorders and decreased hemoglobin.

[0003] NLR family CARD domain-containing protein 5 (NLRC5) is composed of 1866 amino acids and is the largest member of the NLR family. NLRC5 is also known as the major histocompatibility complex (MHC) class I transactivator, and its best feature is that it is regulated as a molecule that transfers between the nucleus and the cytoplasm. In recent years, NLRC5 has attracted much attention in the study of inflammatory immune diseases. Studies have shown that NLRC5 polymorphisms affect susceptibility to chronic periodontitis and pulmonary aspergillosis. In the aseptic hemolytic disease model, NLRC5 knockout mice are free from inflammation, tissue damage and lethality, and are free from lethality in the colitis and hemophagocytic lymphohistiocytosis (HLH) models. In addition, studies have reported that NLRC5 in serum can be used as a diagnostic marker for IgA nephritis. However, NLRC5 as a diagnostic marker has not been reported in the diagnosis of sepsis. Summary of the invention

[0004] The object of the present invention is to provide an application of NLRC5 in preparing a sepsis diagnostic kit.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions: Application of NLRC5 in the preparation of a sepsis diagnostic kit, wherein the sepsis diagnostic kit uses NLRC5 as a biological marker of IgA.

[0006] Preferably, when detected by the sepsis diagnostic kit, the level of NLRC5 in the plasma of sepsis patients is increased.

[0007] Preferably, the sepsis diagnostic kit uses methods including enzyme-linked immunosorbent assay technology for detection, but is not limited to the detection method of enzyme-linked immunosorbent assay technology.

[0008] Preferably, the sepsis diagnostic kit is an ELISA detection kit.

[0009] Preferably, the ELISA detection kit comprises: a microwell ELISA plate, a standard corresponding to NLRC5, a sample diluent, a detection antibody labeled with horseradish peroxidase (HRP), a washing buffer, a substrate, a stop solution and a sealing film.

[0010] Preferably, the sample diluent is phosphate buffer.

[0011] Preferably, the washing buffer is prepared from 8 g of sodium chloride, 0.2 g of potassium dihydrogen phosphate, 3 g of disodium hydrogen phosphate, 5 g of potassium chloride, 2 ml of Tween-20, and 20 ml of distilled water.

[0012] Preferably, the substrate comprises 2%wt hydrogen peroxide and 0.5%wt TMB colorimetric solution.

[0013] Preferably, the stop solution is 2% vol dilute sulfuric acid.

[0014] Compared with the prior art, the present invention has the following beneficial effects: The present invention proposes that a sepsis diagnostic kit uses NLRC5 as a biological marker of IgA, and uses plasma diagnostic technology. It has the advantages of simple operation, non-intervention, high throughput, and low cost in the diagnosis of adult sepsis, and the sepsis diagnostic kit of the present invention has high specificity and good sensitivity. First, when NLRC5 in the plasma of sepsis patients from June 2023 to December 2023 was used to diagnose sepsis patients, the AUC value was 0.8889, the optimal limit corresponding to the sensitivity was 73.33%, and the specificity was 93.33%. In addition, the plasma of sepsis patients and control group patients from January 2024 to July 2024 was collected for verification, and it was found that NLRC5 had an AUC value of 0.8857, a sensitivity of 71.43% corresponding to the optimal limit, and a specificity of 100.00% when diagnosing sepsis. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is a comparison chart of the plasma levels of NLR family CARD domain protein 5 in the control group and sepsis patients detected by enzyme-linked immunosorbent assay technology.

[0016] Figure 2 : This is the ROC curve of the plasma of the NLRC5 control group and the sepsis group in Example 1.

[0017] Figure 3These are the test results of NLRC5 levels in the plasma of the control group and the sepsis group in Example 2 of the present invention.

[0018] Figure 4 : This is the ROC curve of the plasma of the NLRC5 control group and the sepsis group in Example 2 of the present invention. DETAILED DESCRIPTION

[0019] In order to make the technical scheme of the present invention more clearly understood by those skilled in the art, the following embodiments are listed for illustration. It should be pointed out that the following embodiments do not limit the protection scope of the present invention.

[0020] The reagents, methods and equipment used in the following examples are all conventional reagents, methods and equipment in the art. The experimental methods in the following examples without specifying specific experimental conditions are usually carried out under conventional experimental conditions or according to the experimental conditions recommended by the manufacturer.

[0021] The ELISA kit used in the following examples was provided by Shanghai Zhenke Biochemical, and the human NLR family CARD domain protein 5 (NLRC5) ELISA detection kit was used to detect the NLRC5 level in plasma (Cat. No.: ZK-15669). Example 1

[0022] 1. Samples and groups.

[0023] Sepsis group: Patients with suspected sepsis were diagnosed according to the Sepsis-3 sepsis diagnostic criteria. Fifteen patients diagnosed with sepsis in the First Affiliated Hospital of Nanchang University from June 2023 to December 2023 were collected.

[0024] Control group: 15 patients with no infectious diseases, blood system diseases or major congenital diseases who were matched with sepsis patients in age and weight during the same period were collected.

[0025] The remaining peripheral blood in EDTA anticoagulation tubes was collected from all included patients, and the plasma was collected by centrifugation and stored in a -80°C refrigerator for enzyme-linked immunosorbent assay to detect NLRC5 levels.

[0026] 2. The level of NLRC5 in plasma was detected using the human NLR family CARD domain protein 5 (NLRC5) ELISA detection kit. The ELISA detection kit includes: microwell ELISA plate, standard corresponding to NLRC5, sample diluent, horseradish peroxidase (HRP) labeled detection antibody, 20× washing buffer, substrate A (hydrogen peroxide 2%wt), substrate B (0.5%wt TMB colorimetric solution), stop solution (2%vol dilute sulfuric acid), and plate sealing film. The sample diluent is phosphate buffer. The washing buffer is prepared from 8g sodium chloride, 0.2g potassium dihydrogen phosphate, 3g disodium hydrogen phosphate, 5g potassium chloride, 2ml Tween-20, and 20ml distilled water.

[0027] The specific detection steps are as follows: 1) Place the ELISA test kit at room temperature for 20 minutes, return to room temperature, take out the strips to be used from the tin foil bag, and seal the unused strips and store them at 4°C.

[0028] 2) According to the number of samples, set up standard wells and sample wells, and add standards of different concentrations to the standard wells at 50ul per well.

[0029] 3) Sample dilution: dilute the patient's plasma sample 5 times with sample diluent, i.e., add 40ul of sample diluent to 10ul of patient's plasma sample and mix well.

[0030] 4) Sample addition: Add 50ul of standards of different concentrations to the standard wells, add 50ul of diluted plasma samples to the sample wells, and add 50ul of ddH2O to the blank wells.

[0031] 5) Add 100ul of horseradish peroxidase (HRP)-labeled detection antibody to each well of the standard and sample, seal the wells with a sealing film, and incubate in a 37°C incubator covered with tin foil in the dark for 60min.

[0032] 6) Discard the liquid, pat dry on absorbent paper, fill each well with washing buffer, let stand for 1 minute, shake off the washing buffer, pat dry on absorbent paper, and repeat this washing process 5 times.

[0033] 7) Add 50ul of substrate A or substrate B to each well and incubate in a 37℃ incubator covered with tin foil in the dark for 15min.

[0034] 8) Add 50ul of stop solution to each well, measure within 15 minutes, and obtain the OD value of each well at a wavelength of 450nm.

[0035] 9) Draw a standard curve: the horizontal axis is the standard concentration, the vertical axis is the OD value, draw a linear regression curve of the standard, and calculate the concentration value of each sample according to the curve equation.

[0036] The level of NLRC5 in the plasma of 15 patients with sepsis and 15 controls was analyzed by enzyme-linked immunosorbent assay. Figure 1 As shown, the results showed that the plasma level of NLRC5 in patients with sepsis was significantly higher than that in the control group (p<0.0001).

[0037] 3. ROC curve analysis.

[0038] like Figure 2 As shown in the figure, when NLRC5 is used to diagnose patients with sepsis, the AUC value is 0.8889, the best limit corresponds to a sensitivity of 73.33%, and a specificity of 93.33%. This shows that NLRC5 has a high specificity for diagnosing sepsis.

[0039] In summary, this example uses NLRC5 as a biological marker of IgA and uses it for sepsis diagnostic indicators. In independent samples, NLRC5 in the plasma of sepsis patients was detected by enzyme-linked immunosorbent assay, which was significantly higher than that in the control group, with an AUC of 0.8889. NLRC5 can be used as an indicator for the diagnosis of sepsis patients, providing a strong reference value for the clinical diagnosis and treatment of sepsis patients. Example 2

[0040] Re-collect samples for testing to verify accuracy.

[0041] 1. Samples and groups.

[0042] Sepsis group: Patients with suspected sepsis were diagnosed according to the Sepsis-3 sepsis diagnostic criteria. Fourteen patients diagnosed with sepsis in the First Affiliated Hospital of Nanchang University from January 2024 to July 2024 were collected.

[0043] Control group: 15 patients with no infectious diseases, blood system diseases or major congenital diseases who were matched with sepsis patients in age and weight during the same period were collected.

[0044] The remaining peripheral blood in EDTA anticoagulation tubes was collected from all included patients, and the plasma was collected by centrifugation and stored in a -80°C refrigerator for enzyme-linked immunosorbent assay to detect NLRC5 levels.

[0045] 2. Detect the level of NLRC5 in plasma using human NLR family CARD domain protein 5 (NLRC5) ELISA detection kit. The ELISA detection kit is the same as that in Example 1.

[0046] The specific detection steps are as follows: 1) Place the ELISA test kit at room temperature for 20 minutes, return to room temperature, take out the strips to be used from the tin foil bag, and seal the unused strips and store them at 4°C.

[0047] 2) According to the number of samples, set up standard wells and sample wells, and add standards of different concentrations to the standard wells at 50ul per well.

[0048] 3) Sample dilution: dilute the patient's plasma sample 5 times, that is, add 40ul of sample diluent to 10ul of the patient's plasma sample and mix well.

[0049] 4) Sample addition: Add 50ul of standards of different concentrations to the standard wells, add 50ul of diluted plasma samples to the sample wells, and add 50ul of ddH2O to the blank wells.

[0050] 5) Add 100ul of horseradish peroxidase (HRP)-labeled detection antibody to each well of the standard and sample, seal the wells with a sealing film, and incubate in a 37°C incubator covered with tin foil in the dark for 60min.

[0051] 6) Discard the liquid, pat dry on absorbent paper, fill each well with washing buffer, let stand for 1 minute, shake off the washing buffer, pat dry on absorbent paper, and repeat this washing process 5 times.

[0052] 7) Add 50ul of substrate A or substrate B to each well and incubate in a 37℃ incubator covered with tin foil in the dark for 15min.

[0053] 8) Add 50ul of stop solution to each well, measure within 15 minutes, and obtain the OD value of each well at a wavelength of 450nm.

[0054] 9) Draw a standard curve: the horizontal axis is the standard concentration, the vertical axis is the OD value, draw a linear regression curve of the standard, and calculate the concentration value of each sample according to the curve equation.

[0055] The level of NLRC5 in the plasma of 14 patients with sepsis and 15 controls was analyzed by enzyme-linked immunosorbent assay. Figure 3 As shown, the results showed that the plasma level of NLRC5 in patients with sepsis was significantly higher than that in the control group (p<0.0001).

[0056] 3. ROC curve analysis.

[0057] like Figure 4 As shown in the figure, when NLRC5 is used to diagnose patients with sepsis, the AUC value is 0.8857, the best limit corresponds to a sensitivity of 71.43%, and the specificity is 100.00%. This shows that NLRC5 has good specificity for diagnosing sepsis.

[0058] Example 1 and Example 2 detect the NLRC5 biomarker in plasma by ELISA, which effectively increases the accuracy of sepsis diagnosis, and has the advantages of simple operation, no intervention, high throughput, low cost, no radiation and other hazards in the diagnosis of sepsis.

[0059] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. Application of NLRC5 in the preparation of sepsis diagnostic kits, It is characterized in that The sepsis diagnostic kit uses NLRC5 as a biological marker of IgA.

2. Use of NLRC5 according to claim 1 in preparing a sepsis diagnostic kit, It is characterized in that When tested by a sepsis diagnostic kit, NLRC5 levels were elevated in the plasma of sepsis patients.

3. Use of NLRC5 according to claim 1 in preparing a sepsis diagnostic kit, It is characterized in that The sepsis diagnostic kit uses enzyme-linked immunosorbent assay technology for detection.

4. Use of NLRC5 according to claim 1 in preparing a sepsis diagnostic kit, It is characterized in that The sepsis diagnostic kit is an ELISA detection kit.

5. Use of NLRC5 according to claim 4 in preparing a sepsis diagnostic kit, It is characterized in that The ELISA detection kit comprises: a microporous enzyme label plate, a standard substance corresponding to NLRC5, a sample diluent, a detection antibody labeled with horseradish peroxidase, a washing buffer, a substrate, a stop solution and a plate sealing film.

6. Use of NLRC5 according to claim 5 in preparing a sepsis diagnostic kit, It is characterized in that The sample diluent is phosphate buffered saline.

7. Use of NLRC5 according to claim 5 in preparing a sepsis diagnostic kit, It is characterized in that The washing buffer solution is prepared from 8 g of sodium chloride, 0.2 g of potassium dihydrogen phosphate, 3 g of disodium hydrogen phosphate, 5 g of potassium chloride, 2 ml of Tween-20, and 20 ml of distilled water.

8. Use of NLRC5 according to claim 5 in preparing a sepsis diagnostic kit, It is characterized in that The substrate includes 2%wt hydrogen peroxide and 0.5%wt TMB color developing solution.

9. Use of NLRC5 according to claim 5 in preparing a sepsis diagnostic kit, It is characterized in that The stop solution is 2% vol dilute sulfuric acid.

Citation Information

Patent Citations

  • Molecular marker for diagnosing primary biliary cholangitis and application thereof

    CN114088939A

  • Application of NOD-like receptor family protein 3 as marker in preparation of reagent for diagnosing or monitoring sepsis immunosuppression

    CN116064764A

  • Marker for diagnosing sepsis and application thereof

    CN116298327A

  • Novel molecules for therapy and diagnosis

    CN118302442A

  • Diagnosis of sepsis or SIRS using biomarker profiles

    US20040097460A1

Cited By

  • Application of ITGA6 in preparation of sepsis diagnosis and illness monitoring reagent or kit

    CN120405150A

  • Use of ITGA6 in preparation of a diagnostic reagent or kit for sepsis

    CN120405150B